NASDAQ:SMTI Sanara MedTech (SMTI) Stock Price, News & Analysis $33.40 -1.64 (-4.68%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$33.00▼$35.5050-Day Range$26.86▼$35.8952-Week Range$26.00▼$43.25Volume12,120 shsAverage Volume17,314 shsMarket Capitalization$292.25 millionP/E RatioN/ADividend YieldN/APrice Target$44.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Sanara MedTech alerts: Email Address Sanara MedTech MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside31.7% Upside$44.00 Price TargetShort InterestBearish5.22% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.91 out of 5 starsMedical Sector790th out of 910 stocksSurgical Appliances & Supplies Industry17th out of 18 stocks 3.5 Analyst's Opinion Consensus RatingSanara MedTech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageSanara MedTech has received no research coverage in the past 90 days.Read more about Sanara MedTech's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.22% of the float of Sanara MedTech has been sold short.Short Interest Ratio / Days to CoverSanara MedTech has a short interest ratio ("days to cover") of 8.3.Change versus previous monthShort interest in Sanara MedTech has recently increased by 6.10%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSanara MedTech does not currently pay a dividend.Dividend GrowthSanara MedTech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SMTI. Previous Next N/A News and Social Media Coverage Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sanara MedTech insiders have not sold or bought any company stock.Percentage Held by Insiders54.10% of the stock of Sanara MedTech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 8.10% of the stock of Sanara MedTech is held by institutions.Read more about Sanara MedTech's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Sanara MedTech is -56.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sanara MedTech is -56.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSanara MedTech has a P/B Ratio of 7.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Sanara MedTech's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About Sanara MedTech Stock (NASDAQ:SMTI)Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.Read More SMTI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SMTI Stock News HeadlinesAugust 14, 2024 | seekingalpha.comSanara MedTech Inc. (SMTI) Q2 2024 Earnings Call TranscriptAugust 12, 2024 | investorplace.comSMTI Stock Earnings: Sanara MedTech Misses EPS, Beats Revenue for Q2 2024September 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.August 12, 2024 | globenewswire.comSanara MedTech Inc. Announces Second Quarter 2024 ResultsAugust 11, 2024 | markets.businessinsider.comSanara MedTech earnings preview: what Wall Street is expectingJuly 30, 2024 | globenewswire.comSanara MedTech Inc. Announces Second Quarter Earnings Release and Conference Call DatesMay 15, 2024 | insidermonkey.comSanara MedTech Inc. (NASDAQ:SMTI) Q1 2024 Earnings Call TranscriptMay 15, 2024 | finance.yahoo.comSanara MedTech Inc (SMTI) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth Amid ...September 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.May 14, 2024 | investorplace.comSMTI Stock Earnings: Sanara MedTech Misses EPS, Beats Revenue for Q1 2024May 13, 2024 | finance.yahoo.comSanara MedTech Inc. Reports First Quarter 2024 Results: Revenue Surges, Losses WidenMay 13, 2024 | globenewswire.comSanara MedTech Inc. Announces First Quarter 2024 ResultsMay 12, 2024 | finance.yahoo.comInsiders own 30% of Sanara MedTech Inc. (NASDAQ:SMTI) shares but individual investors control 32% of the companyApril 29, 2024 | globenewswire.comSanara MedTech Inc. Announces First Quarter Earnings Release and Conference Call DatesApril 18, 2024 | globenewswire.comSanara MedTech Inc. Announces $55 Million Debt FacilityApril 11, 2024 | investing.comSanara Medtech Inc (SMTI)April 5, 2024 | markets.businessinsider.comSanara MedTech Names Jake Waldrop COO, Effective April 15; Stock Up In Pre-marketApril 5, 2024 | globenewswire.comSanara MedTech Inc. Announces the Appointments of Jake Waldrop as Chief Operating Officer and Tyler Palmer as Chief Corporate Development and Strategy OfficerSee More Headlines Receive SMTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sanara MedTech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/12/2024Today9/07/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical appliances & supplies Sub-IndustryMedical Equipment Current SymbolNASDAQ:SMTI CUSIPN/A CIK714256 Webwww.wndm.com Phone(817) 529-2300FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Stock Price Target$44.00 High Stock Price Target$44.00 Low Stock Price Target$44.00 Potential Upside/Downside+31.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,300,000.00 Net Margins-9.07% Pretax Margin-9.23% Return on Equity-15.17% Return on Assets-8.94% Debt Debt-to-Equity Ratio0.35 Current Ratio1.80 Quick Ratio1.49 Sales & Book Value Annual Sales$64.99 million Price / Sales4.50 Cash FlowN/A Price / Cash FlowN/A Book Value$4.73 per share Price / Book7.06Miscellaneous Outstanding Shares8,750,000Free Float3,959,000Market Cap$292.25 million OptionableNot Optionable Beta1.60 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Ronald T. Nixon (Age 68)Executive Chairman & CEO Comp: $100kMr. Michael D. McNeil (Age 59)CFO & Corporate Secretary Comp: $331.1kMr. Jacob A. WaldropChief Operating OfficerMr. Bill FitzgeraldChief Compliance OfficerMs. Tricia MattesonVice President of MarketingMr. Tyler PalmerChief Corporate Development & Strategy OfficerDr. Christopher A. Morrison FACHM (Age 54)FAPWCA, FCCWS, M.D., President of Telehealth Services Comp: $156kDr. Rebecca Erin Mcmahon (Age 39)President of Research & Development Mr. Seth YonPresident of CommercialMr. Callon NicholsVice President of Corporate OperationsMore ExecutivesKey CompetitorsEstablishment LabsNASDAQ:ESTABioLife SolutionsNASDAQ:BLFSAvanos MedicalNYSE:AVNSSilk Road MedicalNASDAQ:SILKArtivionNYSE:AORTView All CompetitorsInstitutional OwnershipRenaissance Technologies LLCSold 800 shares on 8/9/2024Ownership: 0.163%View All Institutional Transactions SMTI Stock Analysis - Frequently Asked Questions How have SMTI shares performed this year? Sanara MedTech's stock was trading at $41.10 at the start of the year. Since then, SMTI stock has decreased by 18.7% and is now trading at $33.40. View the best growth stocks for 2024 here. How were Sanara MedTech's earnings last quarter? Sanara MedTech Inc. (NASDAQ:SMTI) posted its quarterly earnings results on Monday, August, 12th. The company reported ($0.41) earnings per share for the quarter. The company earned $20.16 million during the quarter. Sanara MedTech had a negative trailing twelve-month return on equity of 15.17% and a negative net margin of 9.07%. Who are Sanara MedTech's major shareholders? Top institutional investors of Sanara MedTech include Renaissance Technologies LLC (0.16%). Insiders that own company stock include Zachary B Fleming and Shawn M Bowman. View institutional ownership trends. How do I buy shares of Sanara MedTech? Shares of SMTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Sanara MedTech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sanara MedTech investors own include Lakeland Industries (LAKE), Ovintiv (OVV), SIG (SHI), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), American Airlines Group (AAL) and Abbott Laboratories (ABT). This page (NASDAQ:SMTI) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sanara MedTech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sanara MedTech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.